STAAR Surgical Announces Q2 2025 Earnings Conference Call and Webcast on August 6, 2025
ByAinvest
Thursday, Jul 31, 2025 10:05 pm ET1min read
STAA--
The live webcast, which includes an option to pre-register, can be accessed at the STAAR website or via the provided link [1]. A webcast replay will be available for at least 90 days following the event.
STAAR Surgical, founded in 1982, specializes in vision correction solutions that reduce or eliminate the need for glasses or contact lenses. The company's EVO family of Implantable Collamer® Lenses (EVO ICL™) offers safe, long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. With over 3 million ICLs sold in more than 75 countries, STAAR Surgical has established itself as a global leader in the IOL market.
The company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICLs, visit www.EVOICL.com, and for additional details about STAAR Surgical, visit www.staar.com.
Investors are encouraged to monitor the company's investor relations section at investors.staar.com for material non-public information and to follow the company's press releases, SEC filings, and public conference calls and webcasts.
References:
[1] https://www.stocktitan.net/news/STAA/staar-surgical-to-host-second-quarter-2025-earnings-conference-call-ufyhep4odaoj.html
[2] https://www.businesswire.com/news/home/20250731973063/en/STAAR-Surgical-to-Host-Second-Quarter-2025-Earnings-Conference-Call-and-Webcast-on-August-6-2025
STAAR Surgical will release Q2 2025 financial results on August 6, 2025, and host an earnings call and webcast at 4:30 p.m. ET. The company will discuss its financial results and business progress. The live webcast can be accessed at the STAAR website, and a replay will be available for at least 90 days. STAAR Surgical is the global leader in implantable phakic intraocular lenses, with a focus on vision correction solutions.
STAAR Surgical Company (NASDAQ: STAA), a leading global provider of implantable phakic intraocular lenses (IOLs), will release its financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025, after the market close. The company will also host an earnings call and webcast at 4:30 p.m. ET to discuss its financial performance and business progress.The live webcast, which includes an option to pre-register, can be accessed at the STAAR website or via the provided link [1]. A webcast replay will be available for at least 90 days following the event.
STAAR Surgical, founded in 1982, specializes in vision correction solutions that reduce or eliminate the need for glasses or contact lenses. The company's EVO family of Implantable Collamer® Lenses (EVO ICL™) offers safe, long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. With over 3 million ICLs sold in more than 75 countries, STAAR Surgical has established itself as a global leader in the IOL market.
The company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICLs, visit www.EVOICL.com, and for additional details about STAAR Surgical, visit www.staar.com.
Investors are encouraged to monitor the company's investor relations section at investors.staar.com for material non-public information and to follow the company's press releases, SEC filings, and public conference calls and webcasts.
References:
[1] https://www.stocktitan.net/news/STAA/staar-surgical-to-host-second-quarter-2025-earnings-conference-call-ufyhep4odaoj.html
[2] https://www.businesswire.com/news/home/20250731973063/en/STAAR-Surgical-to-Host-Second-Quarter-2025-Earnings-Conference-Call-and-Webcast-on-August-6-2025

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet